28 . 03 .2026
Press release
AAD 2026: Late-breaking nemolizumab data demonstrate clinically meaningful benefits for children aged 2 to 11 with moderate-to-severe atopic dermatitis
24 . 03 .2026
Press release
AAD 2026: Galderma showcases latest evidence supporting its full-spectrum, science-driven solutions for diverse skin needs
23 . 03 .2026
Press release
Galderma receives U.S. FDA approval for Restylane® Contour™ for the correction of temple hollowing
20 . 03 .2026
Press release
Galderma publishes invitation and agenda for its 2026 Annual General Meeting
17 . 03 .2026
Press release
AMWC 2026: Galderma showcases category‑leading innovation with a comprehensive portfolio and holistic, future‑focused aesthetic strategies
17 . 03 .2026
News story
AMWC Monaco 2026: Galderma’s scientific presentations and activities
11 . 03 .2026
Press release
Galderma buys back shares worth CHF 232 million in the context of accelerated bookbuild offering
11 . 03 .2026
Press release
Galderma completes successful placement of EUR 500 million Eurobond
